###begin article-title 0
###xml 59 60 59 60 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor
###end article-title 0
###begin p 1
###xml 33 57 33 57 <email xmlns:xlink="http://www.w3.org/1999/xlink">s.romagnani@dmi.unifi.it</email>
CORRESPONDENCE Sergio Romagnani: s.romagnani@dmi.unifi.it
###end p 1
###begin p 2
This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see ). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at ).
###end p 2
###begin p 3
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD161</italic>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 390 391 390 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 401 402 401 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 674 675 671 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 678 679 675 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 59 64 <span type="species:ncbi:9606">human</span>
###xml 593 598 <span type="species:ncbi:9606">human</span>
We demonstrate that CD161 is a highly up-regulated gene in human interleukin (IL) 17 T helper cell (Th17) clones and that all IL-17-producing cells are contained in the CD161+ fraction of CD4+ T cells present in the circulation or in inflamed tissues, although they are not CD1-restricted natural killer T cells. More importantly, we show that all IL-17-producing cells originate from CD161+ naive CD4+ T cells of umbilical cord blood, as well as of the postnatal thymus, in response to the combined activity of IL-1beta and IL-23. These findings implicate CD161 as a novel surface marker for human Th17 cells and demonstrate the exclusive origin of these cells from a CD161+CD4+ T cell progenitor.
###end p 3
###begin p 4
Abbreviations used: APC, allophycocyanin; CD, Crohn's disease; CLEC2, C-type lectin domain family 2; iNKT, invariant NKT; MNC, mononuclear cell; NKT, natural killer T; PB, peripheral blood; PPD, purified protein derivative; RORgammat, retinoic acid-related orphan receptor gammat; TREC, TCR excision circle; UCB, umbilical cord blood.
###end p 4
###begin p 5
L. Cosmi and R. De Palma contributed equally to this paper.
###end p 5
###begin p 6
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib1">1</xref>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib2">2</xref>
###xml 526 527 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib3">3</xref>
###xml 566 567 562 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 645 646 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib4">4</xref>
###xml 648 649 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib5">5</xref>
###xml 800 801 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib6">6</xref>
###xml 1000 1001 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1003 1004 991 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1074 1075 1062 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1200 1201 1185 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib9">9</xref>
###xml 1202 1204 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib11">11</xref>
###xml 1314 1316 1296 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1363 1365 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1478 1480 1454 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 1546 1547 1519 1520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1608 1610 1581 1583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib12">12</xref>
###xml 1611 1613 1584 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib14">14</xref>
###xml 1771 1772 1737 1738 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1893 1895 1859 1861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib15">15</xref>
###xml 2122 2124 2088 2090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib16">16</xref>
###xml 2395 2397 2354 2356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 2601 2602 2556 2557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 2907 2908 2858 2859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 3017 3018 2968 2969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 3020 3021 2971 2972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 639 643 <span type="species:ncbi:10090">mice</span>
###xml 804 809 <span type="species:ncbi:9606">Human</span>
###xml 853 858 <span type="species:ncbi:10090">mouse</span>
###xml 1033 1038 <span type="species:ncbi:10090">mouse</span>
###xml 1220 1225 <span type="species:ncbi:9606">human</span>
###xml 1521 1526 <span type="species:ncbi:9606">human</span>
###xml 1750 1755 <span type="species:ncbi:9606">human</span>
###xml 1936 1942 <span type="species:ncbi:9606">humans</span>
###xml 1947 1951 <span type="species:ncbi:10090">mice</span>
###xml 1973 1978 <span type="species:ncbi:9606">human</span>
###xml 2114 2120 <span type="species:ncbi:9606">humans</span>
###xml 2263 2268 <span type="species:ncbi:9606">human</span>
###xml 2336 2341 <span type="species:ncbi:9606">human</span>
###xml 2451 2456 <span type="species:ncbi:9606">human</span>
###xml 2827 2832 <span type="species:ncbi:9606">human</span>
###xml 2999 3004 <span type="species:ncbi:9606">human</span>
Classically, naive CD4+ T cells have been thought to differentiate into two main lineages, Th1 and Th2 cells (1, 2). Th1 cells produce the signature cytokine IFN-gamma, with the cytokine IL-12 produced by DCs being critical for their differentiation by inducing the activation of STAT-4 and up-regulation of T-bet transcription factor. In contrast, Th2 cells produce IL-4, IL-5, IL-9, and IL-13, and their development is usually started by IL-4 signaling with the participation of the transcription factors STAT-6 and GATA-3 (3). More recently, a third subset of CD4+ effector T cells that produce IL-17, named Th17, has been described in mice (4, 5). These cells express a transcription factor different from those of Th1 and Th2 cells, the retinoic acid-related orphan receptor gammat (RORgammat) (6). Human Th17 cells were found to be different from mouse Th17 cells not only with regard to some phenotypic and functional features, but mainly because of their different mechanisms of development (7, 8). Several papers agree that mouse Th17 cells originate from naive CD4+ T cells in the presence of IL-6 and TGF-beta, and their development is then stabilized and/or amplified by IL-23 and IL-21 (9-11). In contrast, human Th17 cells seem to originate in response to the combined activity of IL-1beta and IL-6 (12), or the activity of IL-1beta or IL-23 alone (13), whereas the combined activity of IL-1beta and IL-23 was not shown to have any additive or synergistic effect (13). Moreover, the addition of TGF-beta to human naive or memory CD4+ T cells was found to inhibit the development of Th17 cells (12-14). In another study, it was reported that IL-1beta and IL-6 up-regulated RORgammat expression but did not induce Th17 differentiation in human adult naive CD4+ T cells, whereas IL-23 was a powerful up-regulator of its own receptor and was an important inducer of IL-17 and IL-22 (15). The discrepancy among results between humans and mice, and among different human studies, with regard to the development of Th17 cells has been attributed to the difficulty to ensure a truly naive cell population in humans (16). More recently, the combined activity of IL-1alpha or IL-1beta and IL-23 was found to be required for the enhancement of IL-17-producing human memory T cells; however, in the same study, the differentiation of human naive T cells into Th17 cells could not be achieved (17). In a previous paper, we showed that in addition to human memory T cells producing IL-17 alone (Th17), there are several T cells in both blood and tissues that coproduce IL-17 and IFN-gamma (Th17/Th1) (8). We also found that these two cell types express both RORgammat and T-bet and that Th17 cells could be shifted to Th1 by the addition of IL-12, an effect that was partially antagonized by IL-23, suggesting a flexibility of human Th17 cells and their possible common developmental origin with Th1 cells (8). Furthermore, we and others identified IL-23R and CCR6 as surface molecules expressed by human Th17 cells (7, 8).
###end p 6
###begin p 7
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD161</italic>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 388 389 388 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 489 490 489 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 499 500 499 500 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 560 561 560 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 597 598 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 601 602 601 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 722 723 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 747 748 744 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 874 875 871 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 885 886 882 883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1117 1118 1114 1115 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1121 1122 1118 1119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 105 110 <span type="species:ncbi:9606">human</span>
###xml 994 999 <span type="species:ncbi:9606">human</span>
###xml 1043 1048 <span type="species:ncbi:9606">human</span>
In this study, by using a microarray assay we found that CD161 was one of the most up-regulated genes in human Th17 clones compared with Th1 or Th2 clones. Accordingly, T blasts from all Th17 clones expressed CD161 on their surface, whereas all Th1 or Th2 clones examined were CD161-. All IL-17-producing cells were found to be included within the CD161+ fraction of adult circulating CD4+ T cells; they were not CD1d-restricted natural killer T (NKT) cells, but NKT-like cells. When CD161+ or CD161- cells were sorted from umbilical cord blood (UCB)-naive CD4+ T cells or from single-positive CD4+CD8- thymocytes and activated in the presence of IL-1beta plus IL-23, Th17, Th17/Th1, or Th1, cells developed from the CD161+ fraction, whereas CD161- cells could never been induced to differentiate into IL-17-producing cells. In contrast, in the presence of IL-12, both CD161+ and CD161- cells only differentiated into Th1 cells. These findings indicate that CD161 is a novel surface marker for human IL-17-producing cells and demonstrate that human Th17 and Th17/Th1 cells exclusively originate from an NKT-like CD161+CD4+ T cell precursor present in the UCB, in the presence of IL-1beta and IL-23 as polarizing cytokines.
###end p 7
###begin title 8
RESULTS
###end title 8
###begin title 9
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Th17, but neither Th1 nor Th2, clones express CD161 on their surface
###end title 9
###begin p 10
###xml 98 99 98 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 462 467 462 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-17</italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-26</italic>
###xml 476 482 476 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-23R</italic>
###xml 484 493 484 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ROR&#947;t</italic>
###xml 499 503 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR6</italic>
###xml 505 506 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 508 509 504 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 511 513 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 531 536 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD161</italic>
###xml 538 546 534 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 A</xref>
###xml 572 573 568 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 917 925 911 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 B</xref>
###xml 1118 1126 1112 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig1" ref-type="fig">Fig. 1 C</xref>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 788 793 <span type="species:ncbi:9606">human</span>
In a previous study, we generated a series of Th1, Th2, and Th17 clones from human circulating CD4+ T cells (8). We performed a microarray analysis to identify possible differences in gene expression by Th17 clones compared with Th1 or Th2 clones. Among genes that fulfilled the criteria described in Materials and methods as up- or down-regulated genes in Th17 versus Th1 or Th2 clones, in addition to those expected on the basis of previous knowledge, such as IL-17, IL-26, IL-23R, RORgammat, and CCR6 (7, 8, 13), there was also CD161 (Fig. 1 A). All genes showing a log2 fold increase or decrease of >/=2.5 in Th17 versus Th1 and Th2 clones are shown in Tables S1-S4 (available at ). Therefore, CD161 expression was analyzed by either quantitative PCR or flow cytometry on a series of human Th1, Th2, or Th17 clones derived from healthy subjects and different from those used for the microarray assay. As shown in Fig. 1 B, Th17 clones expressed higher levels of CD161 mRNA than Th1 and Th2 clones, and virtually all of their T blasts expressed CD161, whereas T blasts from all Th1 and Th2 clones examined did not (Fig. 1 C). CD161 expression by resting Th17 clones was not affected by anti-CD3 plus anti-CD28 mAb stimulation in the presence of IL-2, and it was not induced on Th1 and Th2 clones (Fig. S1).
###end p 10
###begin p 11
###xml 0 52 0 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Human Th17 clones express the NKT cell marker CD161.</bold>
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Th17 clones express the NKT cell marker CD161. (A) Volcano plot representation (log2 fold change vs. t test p-value) between Th17 and Th1 (left) or Th2 (right) cell gene expression profiles. (B) CD161 mRNA levels were measured by real-time quantitative RT-PCR in Th1, Th2, and Th17 clones. Bars represent mean values +/- SE obtained in 10 clones from each type different from those used for the microarray assay. (C) Representative flow cytometric analysis of CD161 surface expression for each type of clone. The gates were placed on the basis of an isotype-matched control mAb. Percentages of gated cells are shown.
###end p 11
###begin title 12
###xml 118 119 118 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
All circulating Th17 cells from adult healthy subjects and Th17 cells from inflamed tissues are contained in the CD161+ fraction
###end title 12
###begin p 13
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 455 456 451 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 495 496 491 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 502 503 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 507 508 503 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 621 622 617 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 732 733 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 744 752 736 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 855 856 847 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 866 867 858 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 972 973 964 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1000 1001 992 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1011 1012 1003 1004 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1094 1095 1082 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1178 1179 1162 1163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1187 1195 1171 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 A</xref>
###xml 1256 1257 1240 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1259 1260 1243 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1328 1336 1312 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1359 1360 1343 1344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1404 1405 1388 1389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1433 1434 1417 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1443 1444 1427 1428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1531 1532 1515 1516 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1565 1566 1549 1550 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1595 1596 1579 1580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1683 1691 1663 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1782 1783 1758 1759 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1787 1788 1763 1764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1804 1812 1780 1788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig2" ref-type="fig">Fig. 2 B</xref>
###xml 1206 1211 <span type="species:ncbi:9606">human</span>
We then asked whether the CD161 expression observed in Th17 clones was also shared by freshly derived circulating Th17 cells. To this end, CD4+ T cells purified from adult PBMCs of healthy subjects were sorted into CD161+ and CD161- cells, and the sorted populations were assessed by flow cytometry for their phenotypic features, as well as for their ability to produce IFN-gamma or IL-17 in response to PMA plus ionomycin stimulation. Virtually all CD161+ cells were contained within the CD45RA-CD45RO+CD31- population (Fig. S2, available at ), suggesting their nature as memory T cells. Moreover, the cells of the CD161+ fraction produced IFN-gamma, IL-17, or both, whereas IL-17-producing cells were virtually absent in the CD161- fraction (Fig. 2 A). Using the same technique, the assessment of the production of IL-21 and IL-22 showed that both CD161- and CD161+ cells were able to produce IL-21, whereas the ability to produce IL-22 was virtually restricted to CD161+ cells (Fig. S3). The CD161+ and CD161- fractions were also tested for RORgammat, IL-23R, and CCR6 mRNA expression. CD161+ T cells expressed higher levels of mRNA for RORgammat, IL-23R, and CCR6 than CD161- cells (Fig. 2 A). Because human Th17 cells have been shown to express CCR6 (7, 8), the association between CCR6 and CD161 was assessed. As shown in Fig. 2 B, the majority of CD161+ T cells also expressed CCR6, and when CD161+ cells were sorted into CCR6- and CCR6+ cells, the great majority of IL-17-producing cells appeared to be included in the CCR6+ fraction. In contrast, the CD161- fraction also contained CCR6+ cells, but they were not capable of producing IL-17, whereas they produced IFN-gamma (Fig. 2 B). Accordingly, RORgammat and IL-23R mRNA expression appeared to be restricted to the CD161+CCR6+ cell fraction (Fig. 2 B).
###end p 13
###begin p 14
###xml 60 61 60 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 124 0 124 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Circulating IL-17&#8211;producing cells are contained in the CD161<sup>+</sup>CCR6<sup>+</sup> fraction of circulating CD4<sup>+</sup> T cells from adult subjects.</bold>
###xml 318 319 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 575 576 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 580 581 566 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 588 589 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 593 594 579 580 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 601 602 587 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 606 607 592 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 618 619 604 605 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 623 624 609 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 628 629 614 615 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Circulating IL-17-producing cells are contained in the CD161+CCR6+ fraction of circulating CD4+ T cells from adult subjects. (A) Detection of IL-17 and IFN-gamma production and expression of RORgammat, IL-23R, and CCR6 mRNA in CD161-depleted (black plot and bars) and CD161-enriched (red plot and bars) circulating CD4+ T cells from healthy adult subjects. Representative flow cytometric analysis (top) and mean values of cytokine-producing cell percentages +/- SE obtained in seven different donors (bottom) are shown. (B) IL-17 and IFN-gamma production in circulating CD161-CCR6-, CD161-CCR6+, CD161+CCR6-, and CD161+CCR6+ CD4+ T cells from one representative experiment out of three performed is shown. RORgammat and IL-23R mRNA expression in the indicated cell populations is shown. Bars represent mean values +/- SE obtained in three separate experiments. Percentages of gated cells are shown.
###end p 14
###begin p 15
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib18">18</xref>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 267 275 267 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 A</xref>
###xml 303 304 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 378 379 378 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 968 969 964 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 972 973 968 969 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 978 979 974 975 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1075 1083 1071 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig3" ref-type="fig">Fig. 3 B</xref>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
To provide evidence of the presence of CD161+ T cells, even in the inflamed tissues where Th17 cells are suspected to play a pathogenic role (18, 19), analysis by confocal microscopy on biopsy specimens of skin from psoriatic patients was also performed. As shown in Fig. 3 A, high percentages of T (CD3+) cells infiltrating the skin of psoriatic patients also coexpressed CD161+, whereas virtually no T cells were observed in control skin specimens of healthy subjects. To further support the results of the confocal microscopy analysis, infiltrating cells were recovered from both the inflamed gut of subjects with Crohn's disease (CD) and the skin of subjects suffering from psoriasis, and expanded in vitro for 7 d with anti-CD3 plus anti-CD28 mAb. Cultured cells were then stimulated with PMA plus ionomycin and examined for the expression of CD161 and for their ability to produce IFN-gamma or IL-17. Virtually all Th17 and Th17/Th1 cells were present in the CD3+CD8-CD161+-gated T cells of both the gut from subjects with CD and the skin from subjects with psoriasis (Fig. 3 B).
###end p 15
###begin p 16
###xml 18 19 18 19 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 100 0 100 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Detection of CD161<sup>+</sup> T cells in inflamed tissues and demonstration of their ability to produce IL-17.</bold>
###xml 468 469 468 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 474 475 474 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 242 249 <span type="species:ncbi:9606">patient</span>
###xml 388 395 <span type="species:ncbi:9606">patient</span>
Detection of CD161+ T cells in inflamed tissues and demonstration of their ability to produce IL-17. (A) Evaluation of the expression of CD3 (red) and CD161 (green) in skin from a healthy donor (top left) or in lesional skin from a psoriatic patient (top right) by confocal microscopy. Arrows point to cells showing double labeling for CD3 and CD161 (yellow) in the skin of the psoriatic patient. TO-PRO-3 (Invitrogen) counterstained nuclei. (bottom) A close-up of CD3+CD161+ double-positive cells (merged; yellow) is shown. Images obtained in the skin of one out of three healthy or psoriatic donors are depicted. Bars, 10 mum. (B) Infiltrating T cells recovered from gut areas of subjects with CD or skin biopsies of subjects with psoriasis were expanded in vitro for 1 wk and assessed for CD161 expression, as well as for their ability to produce IFN-gamma and IL-17 after stimulation with PMA plus ionomycin. Representative flow cytometric analysis obtained in one out of three subjects with CD and in one out of three subjects with psoriasis are shown. Percentages of gated cells are shown.
###end p 16
###begin title 17
###xml 17 18 17 18 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Circulating CD161+ Th17 cells are not NKT cells, but NKT-like cells
###end title 17
###begin p 18
###xml 135 136 135 136 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 143 144 143 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 191 192 191 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 276 277 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 568 576 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 A</xref>
###xml 772 773 762 763 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 776 777 766 767 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 891 892 881 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 897 898 887 888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1022 1030 1012 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 B</xref>
###xml 1146 1147 1132 1133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1284 1292 1270 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig4" ref-type="fig">Fig. 4 C</xref>
Because CD161 has been reported to be expressed by different cell types, including type I or II NKT cells or NKT-like cells (either CD4+ or CD8+ T cells; reference 20), we asked whether CD161+ Th17 cells belonged to the NKT or the NKT-like T cell population. Circulating CD161+CD4+ T cells containing IL-17-producing cells were not type I (or classical) invariant NKT (iNKT) cells because they had a polyclonal Valpha24 TCR chain and exhibited a broad TCR Vbeta repertoire, as shown by spectratyping analysis of both freshly isolated and 1-wk in vitro-expanded cells (Fig. 4 A). In addition, the presence of a broad TCR Vbeta repertoire also excluded the possibility that these cells belong to the type II (nonclassical) NKT cells. Moreover, the response of purified CD161+CD4+ circulating T cells to allogeneic stimulation, as assessed by CD154 expression, was comparable to that of the CD4+CD161- cell fraction, and, more importantly it could be inhibited by the addition in culture of a blocking anti-MHC class II mAb (Fig. 4 B). Furthermore, the expression of IFN-gamma and IL-17 in a purified protein derivative (PPD)-specific short-term CD4+ T cell line stimulated with PPD-loaded autologous DCs was equally inhibited by an anti-MHC class II mAb, as assessed by flow cytometry (Fig. 4 C).
###end p 18
###begin p 19
###xml 15 16 15 16 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 21 22 21 22 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Circulating CD4<sup>+</sup>CD161<sup>+</sup> Th17 cells are not NKT, but NKT-like, cells.</bold>
###xml 270 271 256 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 276 277 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 282 283 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 292 293 278 279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 299 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 342 343 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 348 349 334 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 357 358 343 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 363 364 349 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 647 648 623 624 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 653 654 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 662 663 638 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 668 669 644 645 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 891 892 865 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Circulating CD4+CD161+ Th17 cells are not NKT, but NKT-like, cells. (A) The TCR Valpha24 and TCR Vbeta repertoires were determined by CDR3 length analysis evaluated by spectratyping. The TCR Valpha24 and TCR Vbeta repertoires were assessed on freshly isolated (total CD4+, CD4+CD161+, and CD4+CD161- T cells) and on 1-wk in vitro-expanded CD4+CD161+ and CD4+CD161- T cells. Representative families of different Vbeta chains assessed (BV3, BV7, BV8, BV9, BV11, BV14, BV21, BV22, and BV23) are depicted. One representative out of three different experiments is shown. CDR3 length analysis of Valpha24 and Vbeta11 in iNKT cells is also shown. (B) CD4+CD161+ and CD4+CD161- T cells were stimulated for 8 h with allogeneic DCs in the presence of an anti-MHC class II or an isotype control mAb, and were then assessed for CD154 expression. Bars represent mean values +/- SE of percentages of CD154+ cells obtained in four different experiments. (C) A PPD-specific short-term T cell line highly enriched in IL-17-producing cells was stimulated for 8 h with PPD-loaded autologous DCs in the presence of an anti-MHC class II or an isotype control mAb. CD154 and cytokine expression were assessed by flow cytometry. Percentages of gated cells are shown.
###end p 19
###begin title 20
IL-17-producing cells develop from UCB-naive T cells only in the presence of IL-1beta plus IL-23
###end title 20
###begin p 21
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 61 66 <span type="species:ncbi:9606">human</span>
To identify conditions permissive for the differentiation of human naive T cells into IL-17-producing cells, we first stimulated purified CD45RA+RO- cells obtained from CD4+ T cells of adult subjects for 7 d with anti-CD3 and anti-CD28 mAbs, in the absence or presence of single cytokines (IL-1beta, IL-6, IL-21, IL-23, and TGF-beta) or of combinations of them. We used flow cytometry to analyze the production of IL-17 after stimulation with PMA plus ionomycin. Under any of the experimental conditions used, cells producing IL-17 could never be observed (unpublished data).
###end p 21
###begin p 22
###xml 7 8 7 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 381 389 370 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 667 675 646 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5 A</xref>
###xml 958 959 929 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1262 1263 1226 1227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1299 1314 1259 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, B and C</xref>
###xml 1384 1385 1341 1342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1450 1465 1403 1418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig5" ref-type="fig">Fig. 5, B and C</xref>
UCB CD4+ T cells were then used as source of naive T cells. These cells were cultured under the same conditions described in the previous paragraph, and their capacity to express mRNA for RORgammat, T-bet, IL-23R, CD161, and IL-17 was assessed. Either IL-1beta or IL-23 significantly up-regulated the expression of mRNA for RORgammat, T-bet, and IL-23R, but not of CD161 or IL-17 (Fig. 5 A). When IL-1beta and IL-23 were added together, there was a further up-regulation of T-bet, RORgammat, and IL-23R, as well as of CD161, mRNA expression in comparison with cultures containing IL-1beta or IL-23 alone; in addition, IL-17 mRNA expression became clearly detectable (Fig. 5 A). In contrast, none of the other cytokines added to the cultures, alone or in different combinations, was able to increase RORgammat, IL-23R, IL-17, or CD161 mRNA expression (Fig. S4, available at ). Intracellular expression of IFN-gamma and IL-17 was also evaluated on the same CD4+ T cell cultures by flow cytometry after stimulation with PMA plus ionomycin. Virtually no cells producing IL-17 and only a few IFN-gamma-producing cells were observed in the absence of cytokines. The addition of either IL-1beta or IL-23, or both, induced a significant increase in the proportion of CD4+ T cells able to produce IFN-gamma (Fig. 5, B and C), but only the combination of both IL-1beta and IL-23 enabled UCB CD4+ T cells to produce IL-17, partly in association with IFN-gamma (Fig. 5, B and C).
###end p 22
###begin p 23
###xml 0 90 0 87 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IL-17&#8211;producing cells can develop from UCB T cells in the presence of IL-1&#946; plus IL-23.</bold>
###xml 94 95 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 708 709 693 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
IL-17-producing cells can develop from UCB T cells in the presence of IL-1beta plus IL-23. CD4+ T cells purified from UCB were stimulated for 7 d with anti-CD3 plus anti-CD28 mAb in the presence or absence of the indicated cytokines. (A) RORgammat, T-bet, IL-23R, CD161, and IL-17 mRNA levels were measured by real-time quantitative RT-PCR. Bars represent mean values +/- SE obtained from 13 donors. (B) Cells were also assessed by flow cytometry for their ability to produce IFN-gamma alone (black bars), IL-17 alone (gray bars), or both (white bars) after stimulation with PMA plus ionomycin. Bars represent mean values +/- SE obtained from 13 donors. (C) Representative flow cytometric analysis on UCB CD4+ T cells after stimulation with anti-CD3 plus anti-CD28 mAb, in the presence or absence of the indicated cytokines, performed after 1 wk (top) or 2 wk (bottom) of in vitro expansion. p-values refer to the comparison between cultures performed in the presence of the indicated cytokines versus those performed in the presence of medium alone. Percentages of gated cells are shown.
###end p 23
###begin title 24
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 67 68 67 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
IL-17-producing cells exclusively originate from a CD161+ naive CD4+ T cell precursor
###end title 24
###begin p 25
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 154 162 154 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 294 295 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 307 308 305 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 334 335 332 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 363 364 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 395 396 393 394 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 406 407 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 634 642 628 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 654 655 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 792 793 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 815 816 805 806 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 850 851 840 841 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 861 862 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 901 909 891 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 A</xref>
###xml 935 936 925 926 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 946 947 936 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 955 956 945 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1325 1340 1301 1316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6, B and C</xref>
###xml 1418 1419 1394 1395 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1430 1438 1406 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 1499 1500 1475 1476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1509 1510 1485 1486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1514 1515 1490 1491 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1586 1594 1558 1566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 B</xref>
###xml 1662 1670 1634 1642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 C</xref>
###xml 1728 1736 1700 1708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
###xml 1755 1756 1727 1728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1766 1767 1738 1739 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1777 1778 1749 1750 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1986 1994 1958 1966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig6" ref-type="fig">Fig. 6 D</xref>
###xml 2041 2042 2013 2014 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2262 2263 2228 2229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2276 2277 2242 2243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2297 2298 2263 2264 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
To investigate whether Th17 cells originated from a naive CD161+ precursor, UCB CD4+ T cells were first assessed for the expression of CD161. As shown in Fig. 6 A, flow cytometric analysis of UCB mononuclear cells (MNCs) showed the presence of a small but clearly detectable (0.76 +/- 0.1% SE; n = 18) CD161+ cell population among CD4+ T cells. Therefore, UCB CD4+ T cells were sorted into CD161- and CD161+ cells. The purity of sorted populations was consistently >95%, as shown in Fig. S5 (available at ). The two sorted cell populations were then assessed for the expression of RORgammat, IL-23R, CCR6, and IL-17 mRNA. As shown in Fig. 6 A, only CD161+ cells showed high levels of mRNA for RORgammat, IL-23R, and CCR6, suggesting the constitutive expression of these molecules in the CD161+, but not in the CD161-, fraction. However, neither CD161+ nor CD161- cells expressed the IL-17 transcript (Fig. 6 A). Therefore, sorted CD161+ and CD161- UCB CD4+ T cells were stimulated for 7 d with anti-CD3 plus anti-CD28 mAb in presence of IL-1beta plus IL-23, or of IL-12 alone, and the expression of RORgammat and T-bet, as well as the type of cytokine produced, was assessed. The addition of IL-1beta plus IL-23 resulted in the up-regulation of T-bet and RORgammat, as well as the appearance of Th1 cells, in both fractions (Fig. 6, B and C), but the development of IL-17-producing cells was only observed in the CD161+ fraction (Fig. 6 C). In contrast, the addition of IL-12 induced in either CD161+ or CD161- CD4+ T cells the expression of high levels of T-bet, but not of RORgammat (Fig. 6 B), and induced both cell fractions to differentiate into Th1 cells (Fig. 6 C). One representative flow cytometric picture is shown in Fig. 6 D (left). When CD161+ and CD161- naive CD4+ T cells were restimulated for an additional 7 d with anti-CD3 plus anti-CD28 mAb in the presence or absence of the polarizing cytokines, the proportion of both Th17 and Th17/Th1 cells was largely increased (Fig. 6 D, right). As already observed for total UCB CD4+ T cells (Fig. S4), neither IL-1beta nor IL-23 alone, nor any other cytokine or cytokine combination, including IL-6 plus TGF-beta, showed the ability to induce the appearance of IL-17-producing cells in either the CD161+ or the CD161- fraction of UCB CD4+ T cells (unpublished data).
###end p 25
###begin p 26
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 148 0 141 <bold xmlns:xlink="http://www.w3.org/1999/xlink">UCB CD161<sup>+</sup>CD4<sup>+</sup> T cells constitutively express ROR&#947;t, IL-23R, and CCR6 mRNA and differentiate into Th17 cells in response to IL-1&#946; plus IL-23.</bold>
###xml 187 188 180 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 208 209 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 365 366 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 453 454 440 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 459 460 446 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 479 480 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 485 486 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1053 1054 1028 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1059 1060 1034 1035 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1080 1081 1055 1056 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1086 1087 1061 1062 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
UCB CD161+CD4+ T cells constitutively express RORgammat, IL-23R, and CCR6 mRNA and differentiate into Th17 cells in response to IL-1beta plus IL-23. (A) Flow cytometric detection of CD161+ cells among UCB CD4+ T cells and measurement of RORgammat, IL-23R, CCR6, and IL-17 mRNA levels in CD161-depleted (black bars) and CD161-enriched (red bars) unstimulated UCB CD4+ T cells. Bars represent mean values +/- SE obtained in seven different donors. (B) CD4+CD161+ (red bars) and CD4+CD161- (black bars) T cells were stimulated for 7 d with anti-CD3 plus anti-CD28 mAb in the presence or absence of the indicated cytokines. RORgammat and T-bet mRNA levels were measured by real-time quantitative RT-PCR. Bars represent mean values +/- SE obtained from six donors. (C) The same cell fractions as in B were assessed by flow cytometry for their ability to produce IFN-gamma and IL-17 after stimulation with PMA plus ionomycin. Bars represent mean values +/- SE obtained from six donors. (D) Representative flow cytometric analysis of cytokine production by CD4+CD161+ (red plots) and CD4+CD161- (black plots) T cells after 1 wk (left) or 2 wk (right) of in vitro expansion. p-values refer to the comparison between cultures performed in the presence of the indicated cytokines versus those performed in the presence of medium alone. Percentages of gated cells are shown.
###end p 26
###begin p 27
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 44 45 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 203 204 203 204 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 246 247 246 247 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 432 433 432 433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 436 437 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 455 456 455 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 540 548 540 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 667 675 667 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 A</xref>
###xml 821 822 821 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 828 829 828 829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 851 852 851 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 874 882 874 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 B</xref>
###xml 926 927 926 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 937 938 937 938 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 946 947 946 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1004 1005 1004 1005 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1011 1012 1011 1012 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1034 1035 1034 1035 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1090 1091 1090 1091 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1179 1180 1179 1180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1200 1201 1200 1201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1236 1237 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1281 1282 1281 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1288 1289 1288 1289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1353 1354 1353 1354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1360 1361 1360 1361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1469 1477 1466 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig7" ref-type="fig">Fig. 7 C</xref>
###xml 1553 1554 1550 1551 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1559 1560 1556 1557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Finally, we asked whether the CD161+ UCB CD4+ T cells that differentiated into Th17 cells were really naive T cells or a small subset of contaminating memory T cells. To this end, freshly derived UCB CD4+ T cells were sorted into CD161+ and CD161- cells, and the expression of some phenotypic markers, as well as the ability to produce cytokines after stimulation with PMA plus ionomycin, were examined. Virtually all purified CD161+CD4+, as well as CD161-, UCB T cells expressed CD45RA (even if often in association with CD45RO) and CD31 (Fig. 7 A, left), and when stimulated with PMA plus ionomycin, they did not show the ability to produce cytokines (except IL-2; Fig. 7 A, right). Moreover, TCR excision circle (TREC) levels were examined in the two sorted populations and compared with those found in purified CD45RA-CD45RO+ adult circulating CD4+ T cells. As shown in Fig. 7 B, TREC levels were quite comparable in CD161+ and CD161- UCB CD4+ T cells and significantly higher than in purified CD45RA-CD45RO+ adult circulating CD4+ T cells. To provide additional evidence that UCB CD161+ T cells that gave origin to Th17 cells were not contaminating memory T cells, the CD161+ fraction of UCB CD4+ T cells was depleted of all CD45RO+ cells (including the double-positive CD45RA+CD45RO+ cells), and the remaining population, consisting only of CD45RA+CD45RO- cells, was stimulated with anti-CD3 plus anti-CD28 mAb in the presence of IL-1beta plus IL-23. As shown in Fig. 7 C, despite the depletion of all cells expressing CD45RO, the remaining CD45RA+CD161+ UCB T cells maintained the ability to differentiate into IL-17-producing cells.
###end p 27
###begin p 28
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 13 14 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">UCB CD161<sup>+</sup>CD4<sup>+</sup> T cells that differentiate into Th17 are naive T cells.</bold>
###xml 249 250 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 272 273 272 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 295 296 295 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 419 420 419 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 425 426 425 426 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 443 444 443 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 449 450 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 470 471 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 505 506 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 517 518 517 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 655 656 653 654 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 688 689 686 687 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 729 730 727 728 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 736 737 734 735 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 818 819 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 825 826 823 824 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 887 888 885 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
UCB CD161+CD4+ T cells that differentiate into Th17 are naive T cells. (A) Representative flow cytometric analysis of CD45RA, CD45RO, and CD31 (left) and cytokine production after stimulation with PMA plus ionomycin (right) by freshly isolated CD161+ (red plots) and CD161- (black plots) UCB CD4+ T cells. Percentages of gated cells are shown. (B) TREC analysis was performed by quantitative PCR on freshly isolated CD4+CD161+ (red bar) or CD4+CD161- (black bar) UCB CD4+ T cells and on circulating CD45RA-CD45RO+ CD4+ T cells from adult donors (white bar). Bars represent mean values +/- SE obtained in three different UCB or PB adult donors. (C) UCB CD4+ T cells were depleted of CD45RO+ cells (including double-positive CD45RA+CD45RO+ cells) by FACS using an anti-CD45RO-APC mAb. The fraction containing only CD45RA+CD45RO- (gray bars) and the fraction containing the remaining CD45RO+ cells (white bars) were activated with anti-CD3/CD28 mAb in the absence (medium) or presence of IL-1beta plus IL-23. Bars represent mean values +/- SE obtained in three different UCB donors.
###end p 28
###begin p 29
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 56 57 56 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 211 212 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 215 216 213 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 289 290 287 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 294 295 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 298 299 296 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 324 330 322 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8</xref>
###xml 349 350 347 348 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 355 356 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 425 433 419 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 A</xref>
###xml 578 579 569 570 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 584 585 575 576 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 608 616 599 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="fig8" ref-type="fig">Fig. 8 B</xref>
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 130 135 <span type="species:ncbi:9606">human</span>
To definitively demonstrate the existence of a CD4+CD161+ precursor of human Th17 cells, experiments using T cells from postnatal human thymuses were also performed. A few (0.65 +/- 0.15% SE) single-positive CD4+CD8- thymocytes were found to express CD161 and could be separated from CD161- CD4+CD8- thymocytes. As shown in Fig. 8, only purified CD4+CD161+ thymocytes constitutively expressed both RORgammat and IL-23R mRNA (Fig. 8 A) and could be induced to differentiate into IL-17-producing cells after polyclonal activation in the presence of IL-1beta and IL-23, whereas CD4+CD161- thymocytes could not (Fig. 8 B).
###end p 29
###begin p 30
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 0 127 0 123 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CD161<sup>+</sup> but not CD161<sup>&#8722;</sup> thymocytes constitutively express ROR&#947;t and IL-23R and can be induced to differentiate to Th17 cells.</bold>
###xml 182 183 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 206 207 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 256 257 248 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 260 261 252 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 443 444 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 449 450 437 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 470 471 458 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 476 477 464 465 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 662 663 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 673 674 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 262 267 <span type="species:ncbi:9606">human</span>
###xml 715 720 <span type="species:ncbi:9606">human</span>
CD161+ but not CD161- thymocytes constitutively express RORgammat and IL-23R and can be induced to differentiate to Th17 cells. (A) RORgammat and IL-23R mRNA levels detected in CD161- (black bars) and CD161+ (red bars) cells sorted from single-positive CD4+CD8- human thymocyte suspensions. Bars represent mean values + SE obtained in three different donors. (B) Representative flow cytometric analysis of IL-17 and IFN-gamma production by CD4+CD161+ (red plots) and CD4+CD161- (black plots) thymocytes after 1 wk of in vitro expansion with anti-CD3/CD28 mAb in the absence (medium) or presence of IL-1beta plus IL-23. Comparable results were obtained with CD161- and CD161+ thymocytes from the other two postnatal human thymuses. Percentages of gated cells are shown.
###end p 30
###begin title 31
DISCUSSION
###end title 31
###begin p 32
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 172 173 172 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 286 287 286 287 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-17</italic>
###xml 451 456 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-26</italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-23R</italic>
###xml 466 475 466 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ROR&#947;t</italic>
###xml 481 485 477 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR6</italic>
###xml 487 488 483 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 490 491 486 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 493 495 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib13">13</xref>
###xml 502 507 498 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD161</italic>
###xml 665 666 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 700 701 696 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 739 740 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 775 776 771 772 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 782 783 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 787 788 783 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1036 1037 1032 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 1039 1040 1035 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 1125 1126 1121 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1148 1149 1144 1145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1239 1240 1231 1232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1244 1245 1236 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1345 1346 1337 1338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1362 1363 1354 1355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1429 1430 1421 1422 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1440 1441 1432 1433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1457 1458 1449 1450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1593 1595 1585 1587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib21">21</xref>
###xml 1653 1655 1645 1647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib22">22</xref>
###xml 42 48 <span type="species:ncbi:9606">humans</span>
###xml 277 282 <span type="species:ncbi:9606">human</span>
###xml 418 423 <span type="species:ncbi:9606">human</span>
###xml 1018 1023 <span type="species:ncbi:9606">human</span>
This study demonstrates that, at least in humans, IL-17-producing CD4+ T cells consistently express CD161 as an unexpected surface marker and originate from an NKT-like CD4+ T cell precursor. These observations originated from the results of a microarray analysis performed on human CD4+ T cell clones. This analysis showed that, in addition to up-regulated genes coding for molecules already known to be expressed by human Th17 cells, such as IL-17, IL-26, IL-23R, RORgammat, and CCR6 (7, 8, 13), the CD161 gene was also highly up-regulated on Th17 compared with either Th1 or Th2 clones. More importantly, all IL-17-producing cells were contained within the CD161+ fraction of adult circulating CD4+ T cells. Of note, virtually all CD161+ cells were contained in the CD45RA-CD45RO+CD31- population, suggesting their nature as memory T cells. Moreover, among these cells there was a strict association between the expression of CD161 and CCR6, a chemokine receptor which has been found to be prevalently expressed by human Th17 cells (7, 8), such that virtually all IL-17-producing cells appeared to be contained in the CCR6+ fraction of the CD161+ population. Accordingly, IL-23R and RORgammat mRNA expression was restricted to the CD161+CCR6+ cell fraction. The ability to produce IL-22 after stimulation was virtually restricted to the CD161+ circulating CD4+ T cells, whereas the production of IL-21 was shared by both CD161+ and CD161- circulating CD4+ T cells. The latter findings are in keeping with previous observations showing that IL-21 production is not restricted to Th17 cells (21), whereas IL-22 and IL-17 are coexpressed by Th17 cells (22).
###end p 32
###begin p 33
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib23">23</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 487 489 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 491 493 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 540 541 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 641 643 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 645 647 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib25">25</xref>
###xml 884 886 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1019 1021 948 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib26">26</xref>
###xml 1023 1025 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib27">27</xref>
###xml 1236 1237 1165 1166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1244 1245 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1255 1257 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib20">20</xref>
###xml 1259 1261 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib28">28</xref>
###xml 1269 1270 1198 1199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1356 1357 1285 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1367 1369 1296 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1470 1472 1399 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1474 1476 1403 1405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 1548 1549 1477 1478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1566 1568 1495 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib29">29</xref>
###xml 1662 1663 1591 1592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1686 1688 1615 1617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib24">24</xref>
###xml 1689 1691 1618 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib32">32</xref>
###xml 1719 1720 1648 1649 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1723 1724 1652 1653 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2343 2344 2265 2266 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2346 2348 2268 2270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib33">33</xref>
###xml 2350 2352 2272 2274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib34">34</xref>
###xml 2447 2448 2369 2370 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2458 2459 2380 2381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2515 2517 2437 2439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib35">35</xref>
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
###xml 479 485 <span type="species:ncbi:9606">humans</span>
###xml 524 528 <span type="species:ncbi:10090">mice</span>
###xml 716 721 <span type="species:ncbi:9606">human</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 1204 1210 <span type="species:ncbi:9606">humans</span>
###xml 1335 1340 <span type="species:ncbi:9606">human</span>
###xml 1527 1532 <span type="species:ncbi:9606">human</span>
###xml 1617 1621 <span type="species:ncbi:10090">mice</span>
###xml 2052 2057 <span type="species:ncbi:9606">human</span>
###xml 2176 2180 <span type="species:ncbi:10090">mice</span>
###xml 2261 2266 <span type="species:ncbi:10090">mouse</span>
###xml 2397 2402 <span type="species:ncbi:10090">mouse</span>
CD161 (or NKR-P1A) is the human homologue of the mouse NK1.1 (23), which is expressed not only on almost all NK cells but also by a subset of T cells that have been named NKT cells (24, 25). The classical, type I NKT cells are alpha-galactosylceramide reactive and CD1d restricted, and use an invariant TCR alpha chain consisting of Valpha14-Jalpha18 and a limited beta chain repertoire dominated by Vbeta 8.2, Vbeta7, or Vbeta2 in mice, and of Valpha24-Jalpha18 with Vbeta11 in humans (24, 25). The iNKT cells, at least in mice, may be CD4+ or double-negative and are able to produce large amounts of different cytokines after stimulation (24, 25). In addition to iNKT, NKT cells not bearing the Valpha24-Jalpha18 (human) or the Valpha14-Jalpha18 (mice) TCR, but still dependent on CD1d antigen presentation, have also been identified and named as nonclassical or type II NKT cells (20). These cells can express diverse but few (Valpha3.2-Jalpha9 and Valpha8) TCR alpha chains and can be identified by CD1d tetramers (26, 27). However, other cell types that express CD161 but are restricted by conventional MHC molecules instead of CD1d and, therefore, exhibit noninvariant TCRs, have been described in humans and named as NKT-like CD4+ or CD8+ T cells (20, 28). CD161+ cells were found to be a minority (about one out of five) among human circulating CD4+ T cells (29), with the great majority of them expressing CD45RO, which suggests their nature as memory T cells (24, 30). In contrast, the percentage of iNKT cells among human circulating CD4+ T cells is <1% (29), which is in contrast with the observations in mice, where the majority of circulating NK1.1+ cells are iNKT cells (24-32). The IL-17-producing CD161+CD4+ T cells described in this study were not CD1d-restricted NKT cells because they had a TCR Valpha and Vbeta repertoire heterogeneity incompatible with CD1d restriction, and their response to allogeneic stimulation or stimulation with a soluble antigen, such as PPD, was inhibited by blocking MHC class II. Despite the fact that human IL-17-producing cells are not iNKT but NKT-like cells, our findings may appear in disagreement with those reported in mice showing that a subset of iNKT cells produces IL-17, but curiously, whereas most mouse iNKT cells express NK1.1 (NKR-P1C), the IL-17-producing iNKT cells are NK1.1- (33, 34). However, by using the microarray assay on mouse NKT cells, production of IL-17 by both NK1.1+ and NK1.1- cells upon activation in vitro has also been reported (35).
###end p 33
###begin p 34
###xml 198 199 198 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 209 210 209 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 385 386 385 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 392 393 392 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 417 418 417 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 477 478 477 478 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 519 520 519 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 526 527 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 563 564 563 564 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 658 659 658 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 781 782 778 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 813 814 810 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 824 825 821 822 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 920 921 913 914 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 990 991 983 984 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1109 1110 1102 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1147 1148 1140 1141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1154 1155 1147 1148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1196 1197 1189 1190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1203 1204 1196 1197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1290 1291 1283 1284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1641 1642 1634 1635 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1652 1653 1645 1646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1661 1662 1654 1655 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1824 1825 1817 1818 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1835 1836 1828 1829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1923 1924 1916 1917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1930 1931 1923 1924 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1937 1938 1930 1931 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1996 1997 1989 1990 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2017 2018 2010 2011 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2060 2061 2053 2054 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2126 2127 2119 2120 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2133 2134 2126 2127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2413 2414 2403 2404 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2454 2455 2444 2445 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2458 2459 2448 2449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2530 2531 2520 2521 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2618 2619 2608 2609 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2621 2622 2611 2612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2638 2639 2628 2629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2690 2692 2680 2682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib17">17</xref>
###xml 2808 2809 2798 2799 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2856 2857 2846 2847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2863 2864 2853 2854 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2892 2893 2882 2883 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2956 2957 2946 2947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2963 2964 2953 2954 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 645 650 <span type="species:ncbi:9606">human</span>
###xml 2481 2486 <span type="species:ncbi:9606">human</span>
The most intriguing observation emerging from this study was the demonstration that not only do human Th17 cells express CD161 during their life, but they can also exclusively originate from a CD161+ naive CD4+ T cell precursor. In agreement with the results previously reported by van Beelen et al. (17), we were unable to induce the development of Th17 cells from the purified CD45RA+CD45RO- (naive) circulating CD4+ T cells of adult subjects. Accordingly, virtually no CD161+ cells were found by us within the CD45RA+CD45RO- population of adult circulating CD4+ T cells. In contrast, in this study small numbers of Th17 cells originated from human UCB CD4+ T cells after polyclonal stimulation with anti-CD3/CD28 mAb in the presence of IL-1beta plus IL-23. Notably, when UCB CD4+ T cells were sorted into CD161- and CD161+ cells, constitutive expression of RORgammat, IL-23R, and CCR6 was found, but only in the CD161+ fraction. More importantly, Th17 cells only developed from the CD161+ fraction and their frequency could reach substantial levels (>20%) after a repeated 2-wk stimulation. Because UCB CD4+ T cells consisted not only of CD45RA+CD45RO- cells but also of double-positive CD45RA+CD45RO+ cells, whose functional nature is difficult to define, the possibility that UCB CD161+ cells give rise to IL-17-producing cells, representing the expansion of a small population of contaminating memory T cells present in the UCB as a consequence of fetal immune system stimulation during pregnancy, could be hypothesized. However, this possibility can be reasonably excluded on the basis of three main observations. First, neither CD161+ nor CD161- UCB CD4+ T cells produced any cytokine in response to stimulation with PMA plus ionomycin except IL-2, which is a functional property of naive T cells. Second, both CD161+ and CD161- cells showed comparable TREC levels, which were significantly higher than those of CD4+CD45RA-CD45RO+ (memory) adult circulating T cells. Third, when the CD161+ fraction of UCB CD4+ T cells was completely deprived of CD45RO+ cells, including those coexpressing CD45RA, the remaining CD45RA+CD45RO- population maintained the ability to differentiate into IL-17-producing cells in response to the stimulation with anti-CD3/CD28 mAb in the presence of IL-1beta plus IL-23. Finally, and more importantly, completely similar results were obtained when the small population of CD161+ cells present among single-positive CD4+CD8- T cells of postnatal human thymuses was assessed. Obviously, why CD161+ UCB or thymic naive T cells can differentiate into Th17 cells, whereas purified CD45RA+RO- circulating CD4+ T cells from adult subjects do not (see Results) (17), remains unclear. However, the latter finding is in keeping with the observation reported in this paper that CD161+ cells are apparently not present in the CD45RA+CD45RO- fraction of circulating CD4+ T cells from adult subjects. Thus, if adult circulating CD45RA+CD45RO- cells contain some Th17 precursors, they are certainly present in much lower proportions than in UCB. One might speculate that Th17 responses are mainly mounted during the perinatal period. However, this would imply that for an effective Th17 response, all possible bacterial pathogens should present themselves during the perinatal period, which is very unlikely. Thus, a more likely possibility to explain why Th17 precursors are more numerous in UCB than in adult blood may be that they migrate very early into tissues, where they can differentiate into IL-17-producing cells even later in life.
###end p 34
###begin p 35
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 274 275 274 275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 465 466 461 462 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 866 868 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib36">36</xref>
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 450 455 <span type="species:ncbi:9606">human</span>
###xml 649 654 <span type="species:ncbi:9606">human</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
The results of this study also support our previous findings suggesting that human Th1 and Th17 cells may have a close developmental relationship (8). We could indeed confirm that a substantial proportion of IL-17-producing cells, even after their development from naive CD4+ T cells, also possess the ability to produce IFN-gamma (Th17/Th1), which may represent an intermediate phenotype between Th1 and Th17 cells. Moreover, we clearly showed that human naive CD4+ T cells can give origin to either Th1 or Th17 cells in the presence of IL-1beta plus IL-23, with the presence of IL-12 being determinant for the Th1 choice. Therefore, the origin of human Th17 cells seems to be more similar to that initially reported in mice, when it was thought to depend on the balance between IL-12 and IL-23 production and their interaction with IL-12R or IL-23R, respectively (36).
###end p 35
###begin p 36
###xml 328 329 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 526 527 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 563 564 552 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 623 625 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib37">37</xref>
###xml 627 629 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib38">38</xref>
###xml 698 699 687 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 709 711 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib30">30</xref>
###xml 735 736 724 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 845 847 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib39">39</xref>
###xml 1164 1166 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib40">40</xref>
###xml 1323 1325 1312 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib41">41</xref>
###xml 1428 1430 1417 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib42">42</xref>
###xml 1569 1571 1558 1560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib19">19</xref>
###xml 1622 1623 1611 1612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1726 1727 1715 1716 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2126 2127 2115 2116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib7">7</xref>
###xml 2129 2130 2118 2119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 2540 2541 2529 2530 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2544 2545 2533 2534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 677 682 <span type="species:ncbi:9606">human</span>
###xml 832 837 <span type="species:ncbi:9606">human</span>
###xml 965 970 <span type="species:ncbi:10090">mouse</span>
###xml 1198 1203 <span type="species:ncbi:9606">human</span>
###xml 1691 1699 <span type="species:ncbi:9606">patients</span>
###xml 2401 2406 <span type="species:ncbi:9606">human</span>
###xml 2473 2479 <span type="species:ncbi:9606">humans</span>
The mechanisms linking together the expression of CD161 and the ability to develop into IL-17-producing cells in the presence of the appropriate cytokines (IL-1beta plus IL-23) are still unclear. Cross-linking of CD161 by a plate-bound anti-CD161 mAb did not exert any effect on the proliferation or cytokine production by CD161+ cells (unpublished data), thus excluding that CD161 ligation may play some role in the expansion or effector functions of these cells. Another more likely explanation is that CD161, present on CD4+ T cells as well as on TCRgammadelta+ cells, is implicated in their transendothelial migration (37, 38). Although CD161 is expressed on a minority of human circulating CD4+ T cells (30), an abundance of CD161+ cells represented the majority of T cells from the epithelial and lamina propria layers of the human colon (39). Recently, it was found that high numbers of Th17 cells are constitutively present in different compartments of the mouse gut, and their numbers correlate with the bacterial load of the gut segments (thus being preeminent in the lamina propria of the colon), whereas low numbers were found in the spleen and liver (40). One physiological ligand for human CD161 has been identified as the lectin-like transcript 1, which belongs to the C-type lectin domain family 2 (CLEC2) (41). Another member of the CLEC2 family, CLEC2A, has been found to be selectively expressed in the skin (42), where Th17 cells migrate in the course of chronic inflammatory disorders, such as contact dermatitis, psoriasis, and atopic dermatitis (19). The results of our study show that several CD161+ cells are present among T cells infiltrating the skin of psoriatic patients and that virtually all CD4+ T cells able to produce IL-17 in the gut of subjects with CD, or in the skin of those suffering from psoriasis, were contained within the cell population expressing CD161. This finding supports the possibility that this molecule plays an important role in favoring transendothelial migration of Th17 effectors into tissues, where they are recruited in response to the CCR6-binding chemokine CCL20 (7, 8). However, it cannot be excluded, as suggested previously in this paragraph, that this molecule is also critical for the transendothelial migration of Th17 precursors early in life. In conclusion, we have identified CD161 as one of the most important surface markers of human IL-17-producing cells, and we have demonstrated that, at least in humans, IL-17-producing cells can only originate from a naive CD161+CD4+ T cell precursor.
###end p 36
###begin title 37
MATERIALS AND METHODS
###end title 37
###begin title 38
Subjects.
###end title 38
###begin p 39
###xml 209 217 <span type="species:ncbi:9606">patients</span>
###xml 553 561 <span type="species:ncbi:9606">children</span>
###xml 764 769 <span type="species:ncbi:9606">Human</span>
UCB samples were obtained from 23 donors. Small bowel specimens were obtained from disease-affected gut areas of three subjects with CD, and skin biopsy specimens were obtained from the lesional skin of three patients affected by psoriasis. Normal skin, taken from the abdominal skin of three healthy volunteers who underwent minor surgery (in whom no cutaneous or systemic inflammatory diseases were diagnosed), served as a control. Peripheral blood (PB) samples were obtained from seven healthy volunteers. Three postnatal thymuses were obtained from children (aged between 3 and 15 d) subjected to cardiac surgery. The procedures and all of the experiments of the study were in accordance with the ethical standards of and approved by the Regional Committee on Human Experimentation.
###end p 39
###begin title 40
Reagents.
###end title 40
###begin p 41
###xml 60 61 60 61 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 132 134 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;5</sup>
###xml 410 415 <span type="species:ncbi:10090">mouse</span>
RPMI 1640 medium (Seromed) was used, supplemented with 2 mM l-glutamine, 1% nonessential amino acids, 1% sodium pyruvate, and 2 x 10-5 M 2-ME (all from Invitrogen), and 10% FCS (HyClone; Invitrogen). Unlabeled or fluorochrome-conjugated anti-CD3, -CD4, -CD8, -CD14, -CD16, -CD19, -CD28, -CD31, -CD34, -CD45RA, -CD45RO, -CD56, -CD154, -CD161, -CCR6, -glycophorin A/B, -TCRgammadelta, -MHC class II (clone Tu39, mouse IgG2a; BD Biosciences), -IFN-gamma, -IL-2, -IL-4, and isotype-matched control mAbs were purchased from BD Biosciences. The fluorochrome-conjugated anti-IL-17, -IL-21 and -IL-22 mAbs were obtained from eBioscience. PMA, ionomycin, and brefeldin A were purchased from Sigma-Aldrich. The cytokines IL-1beta, IL-6, IL-12, IL-23, and TGF-beta were purchased from R&D Systems. IL-21 was purchased from Invitrogen.
###end p 41
###begin title 42
###xml 3 4 3 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
CD4+ T cell recovery and expansion.
###end title 42
###begin p 43
###xml 108 109 108 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 249 250 249 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 821 822 813 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 860 861 852 853 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 871 872 863 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1034 1035 1026 1027 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1040 1041 1032 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1049 1050 1041 1042 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1055 1056 1047 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1606 1607 1590 1591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1612 1613 1596 1597 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1621 1622 1605 1606 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1627 1628 1611 1612 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1833 1834 1817 1818 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1839 1840 1823 1824 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1848 1849 1832 1833 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1854 1855 1838 1839 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 1903 1904 1887 1888 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1913 1914 1897 1898 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2199 2200 2179 2180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2212 2213 2192 2193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2218 2219 2198 2199 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2274 2275 2254 2255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2281 2282 2261 2262 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2709 2710 2689 2690 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 2716 2717 2696 2697 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 2723 2724 2703 2704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3045 3046 3025 3026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 3062 3063 3042 3043 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 3191 3192 3171 3172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 3376 3377 3356 3357 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 3436 3437 3416 3417 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 220 225 <span type="species:ncbi:9606">human</span>
###xml 651 655 <span type="species:ncbi:9925">goat</span>
###xml 661 666 <span type="species:ncbi:10090">mouse</span>
MNC suspensions were obtained from UCB and PB by centrifugation on Ficoll-Hypaque gradient. Isolation of CD4+ T cells from UCB or PBMCs was performed by using the CD4 isolation kit II (Miltenyi Biotec). For isolation of human single-positive CD4+CD8- thymocytes, thymic tissue fragments were mechanically disrupted with a MEDI machine (BD Biosciences). MNCs were separated from the other cells by Ficoll-Hypaque gradient centrifugation. Thymic MNC suspensions were incubated for 20 min with anti-CD8, -CD14, -CD16, -CD19, -CD34, -CD56, -TCRgammadelta, and -glycophorin A/B mAbs and extensively washed, and then incubated for an additional 20 min with goat anti-mouse microbead-conjugated polyclonal antibody (Miltenyi Biotec). After washing, cells were separated on a CS+ column. Purified UCB-, PB- and thymus-derived CD4+ cells were further divided into CD161+ and CD161- cells by an anti-CD161-PE or -allophycocyanin (APC) mAb, followed by an anti-PE or -APC microbead mAb (Miltenyi Biotec). Purified UCB, PB, and thymus-derived CD4+CD161+ and CD4+CD161- T cells were (a) analyzed by flow cytometry for surface marker expression, (b) stimulated for intracellular cytokine detection, (c) analyzed by quantitative PCR for gene expression, and (d) stimulated for 7 d with 5 mug/ml anti-CD3 plus 5 mug/ml anti-CD28 mAbs in the absence or presence of 10 ng/ml IL-1beta, 2 ng/ml IL-6, 2 ng/ml IL-12, 20 ng/ml IL-23, 5 ng/ml TGF-beta, or 50 ng/ml IL-21, or combinations of them. On day 7, T cells were analyzed by quantitative PCR for gene expression and stimulated for intracellular cytokine detection. UCB CD4+CD161+ and CD4+CD161- T cell lines were restimulated under the same conditions described for an additional 7 d and were then analyzed by flow cytometry for intracellular cytokine production. In an additional experiment, PB CD4+CD161+ and CD4+CD161- T cell populations were further divided in CCR6+ and CCR6- cell fractions by a FACSAria (BD Biosciences); each purified T cell population was analyzed by quantitative PCR for IL-23R and RORgammat mRNA expression and by flow cytometry for intracellular cytokine production after PMA plus ionomycin stimulation. In additional experiments, PB CD4+ and UCB CD4+CD161+ T cell populations were further purified in the CD45RA+CD45RO- cell fraction by using CD45RO microbead (MACS; Miltenyi Biotec) or CD45RO-APC (FACSAria) mAbs. For isolation of T lymphocytes from the gut and skin biopsies, tissues fragments were mechanically disrupted with a MEDI machine. Cell suspensions were stimulated for 7 d with anti-CD3 plus anti-CD28 mAbs in the presence of 20 IU/ml IL-2. On day 7, T cells were analyzed by flow cytometry for intracellular cytokine production. CD4+CD45RA-CD45RO+ memory T cells used for TREC analysis were obtained by using the CD4 isolation kit II, and CD45RA depletion was performed by using an anti-CD45RA microbead mAb (Miltenyi Biotec). T cell clones were generated from the PBMCs of adult healthy donors and categorized into Th1, Th2, and Th17 subsets, as reported previously (8). In brief, CD4+ cells were seeded under limiting-dilution conditions (0.5 cells per well) in round-bottom microwell plates (Nunc) containing 105 irradiated (6,000 rad) allogeneic PBMCs as feeder cells, 1% PHA (vol/vol), and 50 U/ml rIL-2. Growing microcultures were then supplemented at weekly intervals with 50 U/ml IL-2 and 105 irradiated allogeneic PBMCs as feeder cells. Recovered CD4+ T cell clones were classified into Th1, Th2, or Th17 subsets on the basis of their ability to produce IFN-gamma, IL-4, or IL-17, respectively, as assessed by single-cell flow cytometry after polyclonal stimulation.
###end p 43
###begin title 44
iNKT cell culture.
###end title 44
###begin p 45
PBMCs were expanded in the presence of 100 U/ml rIL-2 and 100 ng/ml alpha-galactosylceramide (ALEXIS Biochemicals) for 2 wk. The cells were then sorted using anti-Vbeta11 and -Valpha24 mAbs (Beckman Coulter).
###end p 45
###begin title 46
Intracellular cytokine and CD154 detection assay.
###end title 46
###begin p 47
###xml 99 100 95 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 105 106 101 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 110 111 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 116 117 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 125 126 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 131 132 127 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 177 178 173 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 465 467 459 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib43">43</xref>
###xml 562 564 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib44">44</xref>
###xml 276 281 <span type="species:ncbi:10090">mouse</span>
Intracellular staining for IFN-gamma, IL-17, IL-4, and IL-2 was performed as previously described (8). 105 CD4+CD161+ and CD4+CD161- cells were cultured with or without 0.5 x 105 irradiated (9,000 rad) allogeneic DCs in the presence of 5 mug/ml anti-MHC class II (clone Tu39, mouse IgG2a) mAb or 5 mug/ml of isotype control mAbs for 8 h, with the last 6 h in the presence of brefeldin A. CD154 detection was performed according to a previously described technique (43). In one experiment, a PPD-specific short-term T cell line, obtained as described previously (44), was stimulated for 8 h (the last 6 h in the presence of brefeldin A) with PPD-loaded autologous DCs in the presence of an anti-MHC class II or an isotype control mAb. Cells were stained for CD3, CD4, CD154, intracellular IFN-gamma, and IL-17, and analyzed by flow cytometry. PPD was obtained from Novartis.
###end p 47
###begin title 48
Confocal microscopy.
###end title 48
###begin p 49
###xml 290 291 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
Detection of CD161 on T cells present in biopsy specimens of normal skin or in lesional skin from psoriatic patients was performed by confocal microscopy on 5-mum sections of frozen skin tissues by using a laser confocal microscope (LSM 510META; Carl Zeiss, Inc.), as previously described (8). For this staining, unlabeled anti-CD3 mAb (clone UCHT1) was obtained from BD Biosciences, and unlabeled anti-CD161 mAb was obtained from Miltenyi Biotec.
###end p 49
###begin title 50
RNA isolation, cDNA synthesis, and real-time quantitative RT-PCR.
###end title 50
###begin p 51
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib8">8</xref>
Total RNA was extracted by using the RNeasy Micro Kit (QIAGEN) and treated with DNase I to eliminate possible genomic DNA contamination. TaqMan RT-PCR was performed, as previously described (8). Primers and probes used were purchased from Applied Biosystems.
###end p 51
###begin title 52
Microarray.
###end title 52
###begin p 53
###xml 28 33 <span type="species:ncbi:9606">human</span>
###xml 113 118 <span type="species:ncbi:9606">Human</span>
###xml 330 335 <span type="species:ncbi:9606">Human</span>
Gene expression profiles on human Th1, Th2, and Th17 clones were assessed by cDNA microarray technique using the Human Genome Survey Microarray (Applied Biosystems). In brief, RNA from different samples was amplified and labeled with Digoxigenin-UTP (DIG-UTP; Applied Biosystems). 10 mug of DIG-labeled cRNA was hybridized to the Human Genome Survey Microarray and read using the 1700 Chemiluminescent Microarray Analyzer (Applied Biosystems). Expression Array System software (Applied Biosystems) was used to analyze the microarrays images. Only microarrays showing a normalized signal intensity >5,000 and a median background <600 were analyzed and normalized using Spotfire and Intergomics software (Spotfire Inc.). Class comparisons expressed as Benjamini-Hochberg false discovery rates were done using parametric tests (LIMMA) after log transformation. Each sample was analyzed three times. Microarray data are available from the Gene Expression Omnibus database under accession no. .
###end p 53
###begin title 54
TCR analysis.
###end title 54
###begin p 55
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 280 286 280 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCR-BV</italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TCR-AV</italic>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib45">45</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 454 456 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 575 577 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 579 581 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
###xml 764 766 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib46">46</xref>
###xml 768 770 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib47">47</xref>
The TCR repertoire was studied by CDR3 length analysis, a well-established PCR-based technique we refer to as spectratyping or immunoscope (45, 46). cDNAs recovered from the different samples and culture conditions described were amplified under nonsaturating PCR conditions with TCR-BV or TCR-AV family-specific primers (45, 46). Each reaction contained a beta-actin-specific primer pair producing a 6-FAM-labeled 230-bp product as an internal control (47). The amount of template cDNA for each sample was assessed by preliminary titration amplifying for total TCR message (46, 47). Each different PCR product was run in a fluorescence-based DNA sequencer (ABI 377; Applied Biosystems) with Rox-labeled size markers (Applied Biosystems), as previously described (46, 47). The data were analyzed using Genescan software (Applied Biosystems) to assign size and peak areas to the different PCR products.
###end p 55
###begin title 56
TREC analysis.
###end title 56
###begin p 57
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib48">48</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="bib49">49</xref>
###xml 622 623 622 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 636 637 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
TRECs were assessed using a procedure that was previously described (48, 49). DNA was extracted by the different cell populations using a RepliQ-mini kit (QIAGEN). The PCR amplification was performed using an ABI 7500 (Applied Biosystems), and primer cycling and conditions have been previously reported (48, 49). As a standard to calculate the number of copies, we used a cloned Sj TREC fragment inserted in the Hind III site of a pUC-19 vector. The number of Sj copies present in a given cell population was calculated by diluting this standard in each PCR experiment. As a control for memory T cells, we used DNA of CD4+CD45RA-CD45RO+ T cells sorted from the PBMCs of a normal donor.
###end p 57
###begin title 58
Statistics.
###end title 58
###begin p 59
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
A standard two-tailed paired t test was used for statistical analysis. P </= 0.05 was considered significant.
###end p 59
###begin title 60
Online supplemental material.
###end title 60
###begin p 61
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 202 203 202 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 289 290 289 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
###xml 300 301 300 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 453 454 449 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 562 563 558 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 590 591 586 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 601 602 597 598 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;</sup>
Fig. S1 shows that CD161 expression by Th17 clones is not affected by in vitro polyclonal activation. Fig. S2 provides an analysis of CD45RA, CD45RO, and CD31 in sorted CD161+ and CD161- circulating CD4+ T cells from adult subjects. Fig. S3 shows the production of IL-21 and IL-22 by CD161- and CD161+ cell fractions from circulating CD4+ T cells of adult subjects. Fig. S4 shows the expression of mRNA for RORgammat, IL-23R, IL-17, and CD161 by UCB CD4+ T cells stimulated in the presence of different cytokines or cytokine combinations. Fig. S5 shows the CD161+ expression by sorted CD161+ and CD161- cell fractions. Tables S1-S4 show microarray data of T cell clones. Online supplemental material is available at .
###end p 61
###begin title 62
Supplementary Material
###end title 62
###begin title 63
[Supplemental Material Index]
###end title 63
###begin p 64
We thank Chiara Romagnani for critical reading and comments.
###end p 64
###begin p 65
This work was supported by the Ministero dell'Istruzione, dell'Universita e della Ricerca (grant PRIN 2005 prot.2005064784_004), the Italian Ministry of Health, the Italian Spatial Agency (MoMa Project), the FP6 European Union project SENS.IT.IV (grant LSHB-CT 2006-018861), INNOCHEM (grant FP6-LSHB-CT2005-518167), Legge 5 Regione Campania (2005), the Associazione Italiana Ricerca sul Cancro, and Ente Cassa di Risparmio di Firenze.
###end p 65
###begin p 66
The authors have no conflicting financial interests.
###end p 66

